Interestingly, MTF oral treatment in both groups of women (Obese + IR and Obese + IR + PCOS groups) induces an increase of APPL1 and a decrease of APPL2 levels in the endometrium (p < 0.05 compared with the control group), independently of the PCOS condition. The gene discussed is APPL2; the disease is polycystic ovary syndrome.